![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1380454
¼¼°èÀÇ ½ÉÀå ÆßÇÁ ±â±â ½ÃÀå(2023-2030³â)Global Heart Pump Device Market 2023-2030 |
¼¼°è ½ÉÀå ÆßÇÁ ±â±â ½ÃÀåÀº ¿¹Ãø ±â°£(2023-2030³â) µ¿¾È 21.4%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÉÇ÷°ü Áúȯ(CVD) ȯÀÚ Áõ°¡, ½ÉºÎÀü ¹ß»ý·ü Áõ°¡¿Í °°Àº ¸Å¿ì Áß¿äÇÑ ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ½ÉÇ÷°ü Áúȯ(CVD)Àº ¼¼°è »ç¸Á ¿øÀÎ 1À§·Î ¸Å³â 1,790¸¸ ¸íÀÇ ¸ñ¼ûÀ» ¾Ñ¾Æ°¡´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ, ½ÉÀå ÆßÇÁ Á¦Ç° ¿¬±¸ ¹× °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ ¼ö¿ë ¹× »ç¿ë Áõ°¡¸¦ ÃËÁøÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.2022³â 10¿ù, Àü Àΰø½ÉÀåÀ» °³¹ßÇÏ´Â ÀüÀÓ»ó ÀÇ·á±â±â ±â¾÷ BiVACOR(R)´Â È£ÁÖ Á¤ºÎ·ÎºÎÅÍ MRFF(Medical Research Future Fund)¿Í TTRA(Targeted Translation Research Accelerator) ÇÁ·Î±×·¥À» ÅëÇØ 75¸¸ ´Þ·¯ÀÇ º¸Á¶±ÝÀ» ¹Þ¾Ò½À´Ï´Ù.
Á¦Ç°º°·Î´Â ½É½Çº¸Á¶ÀåÄ¡(VAD)ÀÌ ¼¼°è ½ÉÀå ÆßÇÁ ½ÃÀå¿¡¼ Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ÀϽÃÀûÀÎ ½ÉºÎÀü ¹ß»ý·ü Áõ°¡, ±âÁõÀÚ ½ÉÀåÀ» »ç¿ëÇÒ ¼ö Àֱ⸦ ±â´Ù¸®´Â µ¿¾È LVADÀÇ ÀϽÃÀûÀÎ »ç¿ë, ¿¬·É ¹× ±âŸ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÉÀå À̽ÄÀ»¹ÞÀ» ¼ö¾ø´Â »ç¶÷µéÀÇ LVAD »ç¿ë Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. 2019³â 10¿ù, ÀÇ·á ±â¼ú ¼±±¸ÀÚÀÎ Medtronic plc´Â ÇöÀç °³¹ß ÁßÀÎ ÁøÇ༺ ½ÉºÎÀü ȯÀÚ¸¦ À§ÇÑ Medtronic Fully Implantable LVAD°¡ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ Çõ½ÅÀû ÀåÄ¡·Î ÁöÁ¤µÇ¾ú½À´Ï´Ù. FDA)·ÎºÎÅÍ Çõ½ÅÀû ÀåÄ¡·Î ÁöÁ¤¹Þ¾Ò½À´Ï´Ù.
¼¼°è ½ÉÀå ÆßÇÁ ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù), À¯·´(¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, µ¶ÀÏ, ÇÁ¶û½º, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Àεµ, Áß±¹, ÀϺ», Çѱ¹, ±âŸ ¾Æ½Ã¾Æ Áö¿ª), ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, ¶óƾ¾Æ¸Þ¸®Ä«)·Î ¼¼ºÐȵǾî ÀÖ½À´Ï´Ù. À¸·Î ¼¼ºÐȵǾî ÀÖ½À´Ï´Ù. ±× Áß¿¡¼µµ ¾Æ½Ã¾ÆÅÂÆò¾çÀº ½ÉºÎÀü À¯º´·ü Áõ°¡¿Í ½ÅÈï±¹ÀÇ °¡Ã³ºÐ ¼Òµæ Áõ°¡¿¡ µû¸¥ ¶óÀÌÇÁ½ºÅ¸ÀÏ º¯È·Î ÀÎÇØ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÆßÇÁ ±â±â ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ¾î ¼¼°è ½ÉÀå ÆßÇÁ ±â±â ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ðµç Áö¿ª Áß ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÉÀ庴 ¹× ³úÁ¹Áß Åë°è 2022(Heart Disease and Stroke Statistics 2022)¿¡ µû¸£¸é, 2019³â ¹Ì±¹¿¡¼ ½ÉÇ÷°ü Áúȯ(CVD)Àº 874,613¸íÀÇ »ç¸ÁÀ» À¯¹ßÇÏ´Â ÁÖ¿ä ¿øÀÎÀ¸·Î ²ÅÇû½À´Ï´Ù. 2019³â ¹Ì±¹¿¡¼´Â ¾à 40Ãʸ¶´Ù 1¸íÀÌ ½É±Ù°æ»öÀ¸·Î »ç¸ÁÇϰí, Æò±Õ 3ºÐ 30Ãʸ¶´Ù 1¸íÀÌ ³úÁ¹ÁßÀ¸·Î »ç¸ÁÇÕ´Ï´Ù. ±×·¯³ª ±âÁ¸ ¼ö¿ä¸¦ ÃæÁ·½ÃŰ±â¿¡ ÃæºÐÇÑ ÀÌ½Ä¿ë ½ÉÀåÀ» ±¸ÇÒ ¼ö ¾ø¾î ºÎÁ· À§±â°¡ ¹ß»ýÇß½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ º¸°ÇÀÚ¿ø¼ºñ½º±¹(HRSA)¿¡ µû¸£¸é 2023³â 9¿ù ÇöÀç ½ÉÀå ÀÌ½Ä ´ë±âÀÚ´Â 3,292¸íÀÔ´Ï´Ù. µû¶ó¼ ½ÉÀå ÆßÇÁ ±â±â´Â ÇâÈÄ ¸î ³âµ¿¾È ¾öû³ ÀÌ¿ë·ü°ú ¼ö¿ä°¡ ¿¹»óµË´Ï´Ù.
Title: Global Heart Pump Device Market Size, Share & Trends Analysis Report by Type (Implanted Heart Pump Devices and Extracorporeal Heart Pump Devices), by Product (Ventricular Assist Devices, Total Artificial Hearts (TAHs), and Extracorporeal Membrane Oxygenation (ECMO)), and by End-User (Hospital and Cardiac Centers)Forecast Period (2023-2030).
The global heart pump device market is anticipated to grow at a CAGR of 21.4% during the Forecast Period (2023-2030). Pivotal factors including the increasing number of individuals suffering from cardiovascular diseases (CVD), rising incidences of heart failure are driving the market growth. According to the World Health Organization, Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. Further, the increasing investment in R&D for heart pump products is projected to drive market growth by promoting increased acceptance and usage of these devices. In October 2022, BiVACOR®, a preclinical medical device company developing a Total Artificial Heart, received a $750k grant from the Australian Government through its medical research future fund (MRFF) and targeted translation research accelerator (TTRA) program.
The global heart pump device market is segmented on the type, and end user. Based on the type, the market is sub-segmented into implanted heart pump devices and extracorporeal heart pump devices. Based on the product, the market is sub-segmented into ventricular assist devices, intra-aortic balloon pumps (IABPs) and extracorporeal membrane oxygenation (ECMO). Further, on the basis of end user, the market is sub-segmented into hospital and cardiac centers. Among the end user, the hospitals sub-segment is anticipated to hold a considerable share of the market, owing to the well-equipped settings, easily accessible, trust and reliability.
Among the product, the ventricular assist devices sub-segment is expected to hold a considerable share of the global heart pump device market. The segmental growth is attributed to the rising incidences of temporary heart failure, temporarily used of LVAD while waiting for a donor heart to become available, increasing use of LVAD who can't have a heart transplant because of age or other factors. Additionally, the rising number of FDA approvals of the products are also contributing to the increasing adoption for LVAD. In October 2019, Medtronic plc, the pioneer in medical technology, received breakthrough device designation from the US Food and Drug Administration (FDA) for the Medtronic Fully Implantable LVAD for patients with advanced heart failure, currently in development.
The global heart pump device market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to the increasing prevalence of heart failure, and the and changes in lifestyles owing to rising disposable income in emerging economies are driving the heart pump device market in the Asia Pacific.
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. The major factors driving the North America market includes the increasing demand for heart transplantation owing to the Cardiovascular diseases' (CVDs) and heart failure. According to the Heart Disease and Stroke Statistics 2022, in 2019, CVD listed as the underlying cause of death, accounted for 874,613 mortalities in the US. In 2019, approximately every 40 seconds, one person in the US suffered with a myocardial infarction and on average people died of stroke every 3 minutes 30 seconds in the country. Though, the unavailability of adequate hearts for transplantation to meet the existing demand resulted in shortage crisis. Furtermore, according to the Health Resources and Services Administration (HRSA) US, as of September 2023, there were 3,292 candidates on heart transplant waiting list. Thus, the heart pump device is expected to witness a huge utilization and demand in the coming years.
The major companies serving the global heart pump device market include: Abbott Laboratories, Berlin Heart GmbH, Boston Scientific Corp., Medtronic plc, Terumo Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2022, Johnson & Johnson Inc. and Abiomed, a global provider in breakthrough heart, lung, and kidney support technologies, entered into a definitive agreement under which Johnson & Johnson acquired through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380.0 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired. The acquisition added heart recovery solutions to complement its Biosense Webster electrophysiology business, allowing the company expand in high-growth markets.